Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (20 ops.)
Latest filing published 14 Sept 2026 for Amylyx Pharmaceuticals, Inc., €801k.
Filing timeline
BuySaleJustin B. Klee
Insider track record
Disclosed buys
0
Disclosed sells
20
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Justin B. Klee: trading record in brief
Justin B. Klee, listed as chief executive, appears in our data through filings on Amylyx Pharmaceuticals, Inc. shares, published by SEC (Form 4). Between 6 January 2022 and 10 September 2026, the trades on record add up to 33 filings.
The open-market record consists of 20 sales worth €7.0M, with no purchase. Besides market trades, the filings include 7 share grants and 5 option exercises. Since January 2026: no purchases and 7 sales on the market.
The latest filing, published on 14 September 2026, reports an open-market sale of €41k in Amylyx Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Justin B. Klee
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations29 total
29,025 shares@ US$32.1293Common StockSEC:0001193125-26-390506:0
1,439 shares@ US$33.1552Common StockSEC:0001193125-26-390506:1
60,039 shares0Common StockSEC:0001193125-26-359678:0
248,865 shares0Common StockSEC:0001193125-26-098437:0
29,282 shares@ US$14.47174.7% of flowCommon StockSEC:0001193125-26-091443:0
15,500 shares@ US$14.6852.5% of flowCommon StockSEC:0001193125-26-037544:0
197,153 shares@ US$7.5719.3% of flowCommon StockSEC:0001193125-26-017056:0
136,193 shares@ US$13.582723.9% of flowCommon StockSEC:0001193125-26-017056:1
2,847 shares@ US$7.570.3% of flowCommon StockSEC:0001193125-26-017056:2
1,995 shares@ US$13.88530.4% of flowCommon StockSEC:0001193125-26-017056:3
7,715 shares@ US$11.09391.0% of flowCommon StockSEC:0001193125-26-007664:0
29,775 shares@ US$14.37285.2% of flowCommon StockSEC:0001193125-25-228343:0
21,490 shares@ US$3.46461.0% of flowCommon StockSEC:0000950170-25-049495:0
180,118 shares0Common StockSEC:0000950170-25-036711:0
4,595 shares@ US$3.1520.2% of flowCommon StockSEC:0000950170-25-033725:0
36,310 shares@ US$1.570.8% of flowCommon StockSEC:0000950170-25-015701:0
11,855 shares@ US$3.46720.6% of flowCommon StockSEC:0000950170-25-014607:0
7,471 shares@ US$4.04250.4% of flowCommon StockSEC:0000950170-25-003533:0
63,690 shares@ US$1.571.4% of flowCommon StockSEC:0000950170-24-122640:0
18,589 shares@ US$3.1970.8% of flowCommon StockSEC:0000950170-24-111812:0
179,850 shares0Common StockSEC:0000950170-24-045694:0
4,135 shares@ US$18.72791.1% of flowCommon StockSEC:0000950170-24-027922:0
126,667 shares0Common StockSEC:0000950170-24-022410:0
5,841 shares@ US$16.32811.3% of flowCommon StockSEC:0000950170-24-003985:0
96,555 shares@ US$31.840543.7% of flowCommon StockSEC:0000899243-23-009182:0
25 of 29 declarations
